Publications

Learn more about our science.

April 2023

Therapeutic potential of EO-3021/SYSA1801, a Claudin 18.2 antibody-drug conjugate, for the treatment of CLDN18.2-expressing cancers

All
Posters & Oral Presentations
Manuscripts

November 08, 2021

Posters & Oral Presentations

CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions

Presented at CCRC 2021

Presenting Author: Natasha Leighl, MD; Princess Margaret Cancer Centre, Toronto, ON, Canada

October 14, 2021

Posters & Oral Presentations

Comprehensive genomic profiling reveals novel opportunities for treatment-refractory gastrointestinal cancers

Presented at AGITG 2021

Wei Yen Chan, The Kinghorn Cancer Centre, St. Vincent’s Hospital, Sydney

July 11, 2021

Manuscripts

Phase 1 dose escalation study of seribantumab (MM-121), an anti-HER3 monoclonal antibody, in patients with advanced solid tumors

Denlinger et al., Investigational New Drugs 2021

April 10, 2021

Posters & Oral Presentations

Preclinical activity of seribantumab in gastrointestinal cancers with NRG1 fusions

Presented at AACR 2021

Presenting Author: Igor Odintsov, MD; Memorial Sloan Kettering Cancer Center

April 06, 2021

Manuscripts

The anti-HER3 monoclonal antibody seribantumab effectively inhibits growth of patient-derived and isogenic cell line and xenograft models with oncogenic NRG1 fusions

Odintsov et al., Clinical Cancer Research 2021

March 29, 2021

Posters & Oral Presentations

CRESTONE – Clinical Study of REsponse to Seribantumab in TumOrs with NEuregulin-1 (NRG1) Fusions

Presented at SGO 2021

Presenting Author: Erika Hamilton, MD; Sarah Cannon Research Institute

Pages: 123

Track our progress

Check back often for our latest insights, or sign up for our mailing list to receive the have the latest news and publications from Elevation Oncology delivered to your inbox.